Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-FL-031 PET in the Diagnosis and Staging of Malignant Tumors
NCT07301801Phase 1Recruiting
- Start
- Jun 2025
- Primary completion
- Sep 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 68Ga-FL-031 in cancer. Primary endpoint: Visual and standardized uptake values assessment of lesions and biodistribution at 1 year. Started Jun 2025; status: recruiting.
02
Drugs
68Ga-FL-031
03
Conditions
cancer
Beyond the preview
Go deeper on NCT07301801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07301801.